Treating primary-progressive multiple sclerosis: potential of ocrelizumab and review of B-cell therapies

References

• PearceJMSHistorical descriptions of multiple sclerosisEur Neurol2005541495316103678
   PubMed Web of Science ®Google Scholar
• The IFNB Multiple Sclerosis Study GroupInterferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trialNeurology19934346556618469318
   PubMed Web of Science ®Google Scholar
• JacobsLDCookfairDLRudickRAIntramuscular interferon beta-1a for disease progression in relapsing multiple sclerosisAnn Neurol19963932852948602746
   PubMed Web of Science ®Google Scholar
• KapposLGroup IMSSJacobsLPlacebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosisLancet19983529139149114979820296
   PubMed Web of Science ®Google Scholar
• KapposLWeinshenkerBPozzilliCInterferon beta-1b in secondary progressive MS: a combined analysis of the two trialsNeurology200463101779178715557490
   PubMed Web of Science ®Google Scholar
• JohnsonKPBrooksBRCohenJACopolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trialNeurology1995457126812767617181
   PubMed Web of Science ®Google Scholar
• JohnsonKPBrooksBRFordCCSustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 yearsMult Scler20006425526610962546
   PubMed Web of Science ®Google Scholar
• WolinskyJSNarayanaPAO’ConnorPGlatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trialAnn Neurol2007611142417262850
   PubMed Web of Science ®Google Scholar
• HartungH-PGonsetteRKönigNMitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trialLancet2000360935020182025
   Web of Science ®Google Scholar
• PolmanCHO’ConnorPWHavrdovaEA randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosisN Engl J Med2006354989991016510744
   PubMed Web of Science ®Google Scholar
• MillerDHKhanOASheremataWAA controlled trial of natalizumab for relapsing multiple sclerosisN Engl J Med20033481152312510038
   PubMed Web of Science ®Google Scholar
• RudickRAStuartWHCalabresiPANatalizumab plus interferon beta-1a for relapsing multiple sclerosisN Engl J Med2006354991192316510745
   PubMed Web of Science ®Google Scholar
• SteinerDArnoldDLFreedmanMSNatalizumab versus placebo in patients with secondary progressive multiple sclerosis (SPMS): results from ASCEND, a multicenter, double-blind, placebo-controlled, randomized phase 3 clinical trialPoster presented at 68th Annual Meeting of the American Academy of NeurologyApril 14, 2016Vancouver, BC
   Google Scholar
• CohenJABarkhofFComiGOral fingolimod or intramuscular interferon for relapsing multiple sclerosisN Engl J Med2010362540241520089954
   PubMed Web of Science ®Google Scholar
• KapposLRadueE-WO’ConnorPA placebo-controlled trial of oral fingolimod in relapsing multiple sclerosisN Engl J Med2010362538740120089952
   PubMed Web of Science ®Google Scholar
• LublinFMillerDHFreedmanMSOral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trialLancet2016387100231075108426827074
   PubMed Web of Science ®Google Scholar
• O’ConnorPWolinskyJSConfavreuxCRandomized trial of oral teriflunomide for relapsing multiple sclerosisN Engl J Med2011365141293130321991951
   PubMed Web of Science ®Google Scholar
• FoxRJMillerDHPhillipsJTPlacebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosisN Engl J Med2012367121087109722992072
   PubMed Web of Science ®Google Scholar
• GoldRKapposLArnoldDLPlacebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosisN Engl J Med2012367121098110722992073
   PubMed Web of Science ®Google Scholar
• NaismithRTPiccioLLyonsJARituximab add-on therapy for breakthrough relapsing multiple sclerosis: a 52-week phase II trialNeurology201074231860186720530322
   PubMed Web of Science ®Google Scholar
• Bar-OrACalabresiPAJArnoldDRituximab in relapsing-remitting multiple sclerosis: A 72-week, open-label, phase I trialAnn Neurol200863339540018383069
   PubMed Web of Science ®Google Scholar
• HawkerKO’ConnorPFreedmanMSRituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trialAnn Neurol200966446047119847908
   PubMed Web of Science ®Google Scholar
• ColesAJTwymanCLArnoldDLAlemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trialLancet201238098561829183923122650
   PubMed Web of Science ®Google Scholar
• CohenJAColesAJArnoldDLAlemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trialLancet201238098561819182823122652
   PubMed Web of Science ®Google Scholar
• FrohmanEMRackeMKRaineCSMultiple Sclerosis — The Plaque and Its PathogenesisN Engl J Med2006354994295516510748
   PubMed Web of Science ®Google Scholar
• KutzelniggALucchinettiCFStadelmannCCortical demyelination and diffuse white matter injury in multiple sclerosisBrain2005128112705271216230320
   PubMed Web of Science ®Google Scholar
• PetersonJWBöLMörkSChangATrappBDTransected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesionsAnn Neurol200150338940011558796
   PubMed Web of Science ®Google Scholar
• MagliozziRHowellOVoraAMeningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathologyBrain2007130Pt 41089110417438020
   PubMed Web of Science ®Google Scholar
• SerafiniBRosicarelliBMagliozziRStiglianoEAloisiFDetection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosisBrain Pathol200414216417415193029
   PubMed Web of Science ®Google Scholar
• SternJNHYaariGVander HeidenJAB cells populating the multiple sclerosis brain mature in the draining cervical lymph nodesSci Transl Med20146248248ra107
   PubMed Web of Science ®Google Scholar
• FranciottaDSalvettiMLolliFSerafiniBAloisiFB cells and multiple sclerosisLancet Neurol20087985285818703007
   PubMed Web of Science ®Google Scholar
• ColomboMDonoMGazzolaPAccumulation of clonally related B lymphocytes in the cerebrospinal fluid of multiple sclerosis patientsJ Immunol200016452782278910679121
   PubMed Web of Science ®Google Scholar
• CorcioneAAloisiFSerafiniBB-cell differentiation in the CNS of patients with multiple sclerosisAutoimmun Rev20054854955416214094
   PubMed Web of Science ®Google Scholar
• RiedhammerCWeissertRAntigen presentation, autoantigens, and immune regulation in multiple sclerosis and other autoimmune diseasesFront Immunol2015632226136751
   PubMed Web of Science ®Google Scholar
• GenainCPCannellaBHauserSLRaineCSIdentification of auto-antibodies associated with myelin damage in multiple sclerosisNat Med1999521701759930864
   PubMed Web of Science ®Google Scholar
• WarrenKGCatzIRelative frequency of autoantibodies to myelin basic protein and proteolipid protein in optic neuritis and multiple sclerosis cerebrospinal fluidJ Neurol Sci1994121166737510787
   PubMed Web of Science ®Google Scholar
• BlauthKSoltysJMatschulatAAntibodies produced by clonally expanded plasma cells in multiple sclerosis cerebrospinal fluid cause demyelination of spinal cord explantsActa Neuropathol2015130676578126511623
   PubMed Web of Science ®Google Scholar
• SrivastavaRAslamMKalluriSRPotassium channel KIR4.1 as an immune target in multiple sclerosisN Engl J Med2012367211512322784115
   PubMed Web of Science ®Google Scholar
• DerfussTParikhKVelhinSContactin-2/TAG-1-directed autoimmunity is identified in multiple sclerosis patients and mediates gray matter pathology in animalsProc Natl Acad Sci U S A2009106208302830719416878
   PubMed Web of Science ®Google Scholar
• FillatreauSSweenieCHMcGeachyMJGrayDAndertonSMB cells regulate autoimmunity by provision of IL-10Nat Immunol200231094495012244307
   PubMed Web of Science ®Google Scholar
• WolfSDDittelBNHardardottirFJanewayCAJrExperimental autoimmune encephalomyelitis induction in genetically B cell-deficient miceJ Exp Med19961846227122788976182
   PubMed Web of Science ®Google Scholar
• YoshizakiAMiyagakiTDiLilloDJRegulatory B cells control T-cell autoimmunity through IL-21-dependent cognate interactionsNature2012491742326426823064231
   PubMed Web of Science ®Google Scholar
• CepokSJacobsenMSchockSPatterns of cerebrospinal fluid pathology correlate with disease progression in multiple sclerosisBrain2001124Pt 112169217611673319
   PubMed Web of Science ®Google Scholar
• CorrealeJde los Milagros Bassani MolinasMOligoclonal bands and antibody responses in multiple sclerosisJ Neurol2002249437538911967640
   PubMed Web of Science ®Google Scholar
• DobsonRRamagopalanSDavisAGiovannoniGCerebrospinal fluid oligoclonal bands in multiple sclerosis and clinically isolated syndromes: a meta-analysis of prevalence, prognosis and effect of latitudeJ Neurol Neurosurg Psychiatry201384890991423431079
   PubMed Web of Science ®Google Scholar
• JenkinsMAChengLRatnaikeSMultiple sclerosis: use of light-chain typing to assist diagnosisAnn Clin Biochem200138Pt 323524111392498
   PubMed Web of Science ®Google Scholar
• SenelMTumaniHLaudaFCerebrospinal fluid immunoglobulin kappa light chain in clinically isolated syndrome and multiple sclerosisPLoS One201494e8868024695382
   PubMed Web of Science ®Google Scholar
• JosephFGHirstCLPickersgillTPBen-ShlomoYRobertsonNPScoldingNJCSF oligoclonal band status informs prognosis in multiple sclerosis: a case control study of 100 patientsJ Neurol Neurosurg Psychiatry200980329229618829628
   PubMed Web of Science ®Google Scholar
• LundkvistMGreinerEHillertJFogdell-HahnAMultiple sclerosis patients lacking oligoclonal bands in the cerebrospinal fluid are less likely to develop neutralizing antibodies against interferon betaMult Scler201016779680020534645
   PubMed Web of Science ®Google Scholar
• AvasaralaJRCrossAHTrotterJLOligoclonal band number as a marker for prognosis in multiple sclerosisArch Neurol200158122044204511735778
   PubMedGoogle Scholar
• FitznerBHeckerMZettlUKMolecular biomarkers in cerebrospinal fluid of multiple sclerosis patientsAutoimmun Rev2015141090391326071103
   PubMed Web of Science ®Google Scholar
• VillarLMCasanovaBOuamaraNImmunoglobulin M oligoclonal bands: biomarker of targetable inflammation in primary progressive multiple sclerosisAnn Neurol201476223124024909126
   PubMed Web of Science ®Google Scholar
• BoscaIVillarLCoretFResponse to interferon in multiple sclerosis is related to lipid-specific oligoclonal IgM bandsMult Scler201016781081520538705
   PubMed Web of Science ®Google Scholar
• BankotiJApeltsinLHauserSLIn multiple sclerosis, oligoclonal bands connect to peripheral B-cell responsesAnn Neurol201475226627624375699
   PubMed Web of Science ®Google Scholar
• CrossAHStarkJLLauberJRamsbottomMJLyonsJ-ARituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patientsJ Neuroimmunol20061801637016904756
   PubMed Web of Science ®Google Scholar
• HauserSLWaubantEArnoldDLB-cell depletion with rituximab in relapsing-remitting multiple sclerosisN Engl J Med2008358767668818272891
   PubMed Web of Science ®Google Scholar
• KapposLLiDCalabresiPAOcrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trialLancet201137898051779178722047971
   PubMed Web of Science ®Google Scholar
• VillarLMGarcía-SánchezMICosta-FrossardLImmunological markers of optimal response to natalizumab in multiple sclerosisArch Neurol201269219119722332187
   PubMedGoogle Scholar
• HarrerATumaniHNiendorfSCerebrospinal fluid parameters of B cell-related activity in patients with active disease during natalizumab therapyMult Scler20131991209121223093485
   PubMed Web of Science ®Google Scholar
• ShiKHayashidaKKanekoMLymphoid chemokine B cell-attracting chemokine-1 (CXCL13) is expressed in germinal center of ectopic lymphoid follicles within the synovium of chronic arthritis patientsJ Immunol2001166165065511123349
   PubMed Web of Science ®Google Scholar
• RandenIMellbyeOJFørreONatvigJBThe identification of germinal centres and follicular dendritic cell networks in rheumatoid synovial tissueScand J Immunol19954154814867725067
   PubMed Web of Science ®Google Scholar
• AmftNCurnowSJScheel-ToellnerDEctopic expression of the B cell-attracting chemokine BCA-1 (CXCL13) on endothelial cells and within lymphoid follicles contributes to the establishment of germinal center-like structures in Sjogren’s syndromeArthritis Rheum200144112633264111710719
   PubMed Web of Science ®Google Scholar
• MosnierJFDegottCMarcellinPHéninDErlingerSBenhamouJPThe intraportal lymphoid nodule and its environment in chronic active hepatitis C: an immunohistochemical studyHepatology19931733663718444410
   PubMed Web of Science ®Google Scholar
• MahadDHTrappBDLassmannHPathological mechanisms in progressive multiple sclerosisLancet Neurol201514218319325772897
   PubMed Web of Science ®Google Scholar
• HowellOWReevesCANicholasRMeningeal inflammation is widespread and linked to cortical pathology in multiple sclerosisBrain2011134Pt 92755277121840891
   PubMed Web of Science ®Google Scholar
• HaugenMFrederiksenJLDegnMB cell follicle-like structures in multiple sclerosis-with focus on the role of B cell activating factorJ Neuroimmunol20142731–21724953530
   PubMed Web of Science ®Google Scholar
• AbsintaMVuoloLRaoAGadolinium-based MRI characterization of leptomeningeal inflammation in multiple sclerosisNeurology2015851182825888557
   PubMed Web of Science ®Google Scholar
• ChoiSRHowellOWCarassitiDMeningeal inflammation plays a role in the pathology of primary progressive multiple sclerosisBrain2012135102925293722907116
   PubMed Web of Science ®Google Scholar
• LiRRezkAMiyazakiYProinflammatory GM-CSF-producing B cells in multiple sclerosis and B cell depletion therapySci Transl Med20157310310ra166
   PubMed Web of Science ®Google Scholar
• MerrillJEWåhlinBSidénAPerlmannPElevated direct and IgM enhanced ADCC activity in multiple sclerosis patientsJ Immunol19821284172817357037955
   PubMed Web of Science ®Google Scholar
• FrickESticklHSpecificity of antibody-dependent lymphocyte cytotoxicity against cerebral tissue constituents in multiple sclerosisActa Neurol Scand198265130376175158
   PubMed Web of Science ®Google Scholar
• RobakTRobakENew anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoid malignanciesBioDrugs2011251132521090841
   PubMed Web of Science ®Google Scholar
• IvanovABeersSAWalsheCAMonoclonal antibodies directed to CD20 and HLA-DR can elicit homotypic adhesion followed by lysosome-mediated cell death in human lymphoma and leukemia cellsJ Clin Invest200911982143215919620786
   PubMed Web of Science ®Google Scholar
• PolyakMJDeansJPAlanine-170 and proline-172 are critical determinants for extracellular CD20 epitopes; heterogeneity in the fine specificity of CD20 monoclonal antibodies is defined by additional requirements imposed by both amino acid sequence and quaternary structureBlood20029993256326211964291
   PubMed Web of Science ®Google Scholar
• TeelingJLMackusWJMWiegmanLJJMThe biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20J Immunol2006177136237116785532
   PubMed Web of Science ®Google Scholar
• BinderMOttoFMertelsmannRVeelkenHTrepelMThe epitope recognized by rituximabBlood200610861975197816705086
   PubMed Web of Science ®Google Scholar
• DuJWangHZhongCCrystal structure of chimeric antibody C2H7 Fab in complex with a CD20 peptideMol Immunol200845102861286818346788
   PubMed Web of Science ®Google Scholar
• de RomeufCDutertreC-ALe Garff-TavernierMChronic lymphocytic leukaemia cells are efficiently killed by an anti-CD20 monoclonal antibody selected for improved engagement of FcγRIIIA/CD16Br J Haematol2008140663564318302712
   PubMed Web of Science ®Google Scholar
• O’ConnerOASchreederMTDengCUblituximab (tg-1101), a novel anti-cd20 monoclonal antibody for rituximab relapsed/refractory b-cell malignancies18th Congress of the European Hematology AssociationStockholm, Sweden2014
   Google Scholar
• ClynesRATowersTLPrestaLGRavetchJVInhibitory Fc receptors modulate in vivo cytotoxicity against tumor targetsNat Med20006444344610742152
   PubMed Web of Science ®Google Scholar
• PalanichamyAJahnSNicklesDRituximab efficiently depletes increased CD20-expressing T cells in multiple sclerosis patientsJ Immunol2014193258058624928997
   PubMed Web of Science ®Google Scholar
• PiccioLNaismithRTTrinkausKChanges in B- and T-lymphocyte and chemokine levels with rituximab treatment in multiple sclerosisArch Neurol201067670771420558389
   PubMed Web of Science ®Google Scholar
• LeeW-JLeeS-TByunJ-IRituximab treatment for autoimmune limbic encephalitis in an institutional cohortNeurology201686181683169127037228
   PubMed Web of Science ®Google Scholar
• ToyoshimaDMorisadaNTakamiYRituximab treatment for relapsed opsoclonus-myoclonus syndromeBrain Dev201638334634926375512
   PubMed Web of Science ®Google Scholar
• IorioRDamatoVAlboiniPEEvoliAEfficacy and safety of rituximab for myasthenia gravis: a systematic review and meta-analysisJ Neurol201526251115111925308632
   PubMed Web of Science ®Google Scholar
• CollonguesNde SezeJAn update on the evidence for the efficacy and safety of rituximab in the management of neuromyelitis opticaTher Adv Neurol Disord20169318018827134673
   PubMed Web of Science ®Google Scholar
• RadaelliMMoiolaLSangalliFNeuromyelitis optica spectrum disorders: long-term safety and efficacy of rituximab in Caucasian patientsMult Scler201622451151926199350
   PubMed Web of Science ®Google Scholar
• BourdetteDRituximab for treating multiple sclerosis: Off-label but on targetNeurology201687202070207127760871
   PubMed Web of Science ®Google Scholar
• SalzerJSvenningssonRAlpingPRituximab in multiple sclerosis: A retrospective observational study on safety and efficacyNeurology201687202074208127760868
   PubMed Web of Science ®Google Scholar
• AlpingPFrisellTNovakovaLRituximab versus fingolimod after natalizumab in multiple sclerosis patientsAnn Neurol201679695095827038238
   PubMed Web of Science ®Google Scholar
• AndersonKCBatesMPSlaughenhouptBLPinkusGSSchlossmanSFNadlerLMExpression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiationBlood1984636142414336609729
   PubMed Web of Science ®Google Scholar
• CarsonKREvensAMRicheyEAProgressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports projectBlood2009113204834484019264918
   PubMed Web of Science ®Google Scholar
• MajorEOProgressive Multifocal Leukoencephalopathy in Patients on Immunomodulatory TherapiesAnnu Rev Med2010611354719719397
   PubMed Web of Science ®Google Scholar
• CliffordDBAncesBCostelloCRituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritisArch Neurol20116891156116421555606
   PubMed Web of Science ®Google Scholar
• CreeBACLambSMorganKChenAWaubantEGenainCAn open label study of the effects of rituximab in neuromyelitis opticaNeurology20056471270127215824362
   PubMed Web of Science ®Google Scholar
• KimS-HHuhS-YLeeSJA 5-Year Follow-up of Rituximab Treatment in Patients With Neuromyelitis Optica Spectrum DisorderJAMA Neurol2013709111023897062
   PubMed Web of Science ®Google Scholar
• PellkoferHLKrumbholzMBertheleALong-term followup of patients with neuromyelitis optica after repeated therapy with rituximabNeurology201176151310131521482945
   PubMed Web of Science ®Google Scholar
• BediGSBrownADDelgadoSRUsmaniNLamBLSheremataWAImpact of rituximab on relapse rate and disability in neuromyelitis opticaMult Scler201117101225123021622594
   PubMed Web of Science ®Google Scholar
• KimS-HJeongIHHyunJ-WTreatment Outcomes With Rituximab in 100 Patients With Neuromyelitis Optica: Influence of FCGR3A Polymorphisms on the Therapeutic Response to RituximabJAMA Neurol201572998999526167726
   PubMed Web of Science ®Google Scholar
• StashenkoPNadlerLMHardyRSchlossmanSFCharacterization of a human B lymphocyte-specific antigenJ Immunol19801254167816856157744
   PubMed Web of Science ®Google Scholar
• StashenkoPNadlerLMHardyRSchlossmanSFExpression of cell surface markers after human B lymphocyte activationProc Natl Acad Sci U S A1981786384838526973760
   PubMed Web of Science ®Google Scholar
• MorschhauserFMarltonPVitoloUResults of a phase I/II study of ocrelizumab, a fully humanized anti-CD20 mAb, in patients with relapsed/refractory follicular lymphomaAnn Oncol20102191870187620157180
   PubMed Web of Science ®Google Scholar
• VugmeysterYBeyerJHowellKDepletion of B cells by a humanized anti-CD20 antibody PRO70769 in Macaca fascicularisJ Immunother200528321221915838377
   PubMed Web of Science ®Google Scholar
• ButtmannMTreating multiple sclerosis with monoclonal antibodies: a 2010 updateExpert Rev Neurother201010579180920420497
   PubMed Web of Science ®Google Scholar
• GasperiniCHaggiagSRuggieriSDrugs in clinical development for multiple sclerosis: focusing on anti-CD20 antibodiesExpert Opin Investig Drugs2013221012431253
   PubMed Web of Science ®Google Scholar
• GenoveseMCKaineJLLowensteinMBOcrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I/II randomized, blinded, placebo-controlled, dose-ranging studyArthritis Rheum20085892652266118759293
   PubMed Web of Science ®Google Scholar
• KausarFMustafaKSweisGOcrelizumab: a step forward in the evolution of B-cell therapyExpert Opin Biol Ther20099788989519463076
   PubMed Web of Science ®Google Scholar
• HauserSLComiGCHartungH-PEfficacy and safety of ocrelizumab in relapsing multiple sclerosis - results of the interferon-beta-1a-controlled, double-blind, Phase III OPERA I and II studiesPoster presented at: 31st Congress of the European Committee for Treatment and Research in Multiple SclerosisSep 23, 2015Barcelona, Spain
   Google Scholar
• WolinskyJArnoldDLBar-OrAEfficacy of ocrelizumab in patients with PPMS with and without T1 gadolinium-enhancing lesions at baseline in a phase iii, placebo-controlled trialPoster presented at Americas Committee for Treatment and Research in Multiple SclerosisJun 3, 2016National Harbor, MD
   Google Scholar
• MontalbanXHemmerBRammohanKEfficacy and Safety of Ocrelizumab in Primary Progressive Multiple Sclerosis: Results of the Phase III Double-Blind, Placebo-Controlled ORATORIO StudyNeurology20168616 SupplS49.001
   Google Scholar
• RigbyWTonyH-POelkeKSafety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: Results of a forty-eight-week randomized, double-blind, placebo-controlled, parallel-group phase III trialArthritis Rheum201264235035921905001
   PubMed Web of Science ®Google Scholar
• TeelingJLFrenchRRCraggMSCharacterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomasBlood200410461793180015172969
   PubMed Web of Science ®Google Scholar
• HillmenPRobakTJanssensAChlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trialLancet201538599801873188325882396
   PubMed Web of Science ®Google Scholar
• ÖsterborgAUdvardyMZaritskeyAPhase III, randomized study of ofatumumab versus physicians’ choice of therapy and standard versus extended-length ofatumumab in patients with bulky fludarabine-refractory chronic lymphocytic leukemiaLeuk Lymphoma20165792037204626784000
   PubMed Web of Science ®Google Scholar
• van OersMHJKuliczkowskiKSmolejLOfatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 studyLancet Oncol201516131370137926377300
   PubMed Web of Science ®Google Scholar
• QuattrocchiEØstergaardMTaylorPCSafety of repeated open-label treatment courses of intravenous ofatumumab, a human anti-CD20 monoclonal antibody, in rheumatoid arthritis: results from three clinical trialsPLoS One2016116e015796127336685
   PubMed Web of Science ®Google Scholar
• SorensenPSLisbySGroveRSafety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis: a phase 2 studyNeurology201482757358124453078
   PubMed Web of Science ®Google Scholar
• Bar-OrAGroveRAustinDThe MIRROR study: a randomized, double-blind, placebo-controlled, parallel-group, dose-ranging study to investigate the safety and MRI efficacy of subcutaneous ofatumumab in subjects with relapsing-remitting multiple sclerosis (RRMS)Neurology20148210S23.006
   Google Scholar
• SørensenPSFollow-up data from the Mirror study: a dose-ranging study of subcutaneous ofatumumab in subjects with relapsing-remitting multiple sclerosisPoster presented at: 2014 Joint ACTRIMS-ECTRIMS MeetingSep 10–13; 2014Boston, MA
   Google Scholar
• ZentCSSecretoCRLaPlantBRDirect and complement dependent cytotoxicity in CLL cells from patients with high-risk early-intermediate stage chronic lymphocytic leukemia (CLL) treated with alemtuzumab and rituximabLeuk Res200832121849185618584865
   PubMed Web of Science ®Google Scholar
• GolayJManganiniMRambaldiAIntronaMEffect of alemtuzumab on neoplastic B cellsHaematologica200489121476148315590398
   PubMed Web of Science ®Google Scholar
• SmolewskiPSzmigielska-KaplonACebulaBProapoptotic activity of alemtuzumab alone and in combination with rituximab or purine nucleoside analogues in chronic lymphocytic leukemia cellsLeuk Lymphoma20054618710015621786
   PubMed Web of Science ®Google Scholar
• The CAMMS223 Trial InvestigatorsAlemtuzumab vs. Interferon Beta-1a in Early Multiple SclerosisN Engl J Med2008359171786180118946064
   PubMed Web of Science ®Google Scholar
• Hill-CawthorneGAButtonTTuohyOLong term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosisJ Neurol Neurosurg Psychiatry201283329830422056965
   PubMed Web of Science ®Google Scholar
• ArnoldDLFisherEBrinarVVSuperior MRI outcomes with alemtuzumab compared with subcutaneous interferon β-1a in MSNeurology201687141464147227590291
   PubMed Web of Science ®Google Scholar
• ColesAJWingMGMolyneuxPMonoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosisAnn Neurol199946329630410482259
   PubMed Web of Science ®Google Scholar
• ColesAJCoxAPageEThe window of therapeutic opportunity in multiple sclerosisJ Neurol200625319810816044212
   PubMed Web of Science ®Google Scholar
• DavidsonATargeting BAFF in autoimmunityCurr Opin Immunol201022673273920970975
   PubMed Web of Science ®Google Scholar
• SchneiderPMacKayFSteinerVBAFF, a novel ligand of the tumor necrosis factor family, stimulates B Cell growthJ Exp Med1999189111747175610359578
   PubMed Web of Science ®Google Scholar
• TakPPThurlingsRMRossierCAtacicept in patients with rheumatoid arthritis: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating, single- and repeated-dose studyArthritis Rheum2008581617218163485
   PubMed Web of Science ®Google Scholar
• Dall’EraMChakravartyEWallaceDReduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trialArthritis Rheum200756124142415018050206
   PubMed Web of Science ®Google Scholar
• Pena-RossiCNasonovEStanislavMAn exploratory dose-escalating study investigating the safety, tolerability, pharmacokinetics and pharmacodynamics of intravenous atacicept in patients with systemic lupus erythematosusLupus200918654755519395457
   PubMed Web of Science ®Google Scholar
• KapposLHartungH-PFreedmanMSAtacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trialLancet Neurol2008134353363
   Web of Science ®Google Scholar
• SchiffMCombeBDörnerTEfficacy and safety of tabalumab, an anti-BAFF monoclonal antibody, in patients with moderate-to-severe rheumatoid arthritis and inadequate response to TNF inhibitors: results of a randomised, double-blind, placebo-controlled, phase 3 studyRMD Open201511e00003726535134
   PubMedGoogle Scholar
• Eli Lilly and CompanyMultiple subcutaneous doses of LY2127399, an anti-BAFF human antibody, in subjects with relapsing-remitting multiple sclerosis Available from: https://clinicaltrials.gov/ct2/show/NCT00882999. NLM Identifier: NCT00882999Accessed August 17, 2016
   Google Scholar
• FurieRPetriMZamaniOA phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosusArthritis Rheum201163123918393022127708
   PubMed Web of Science ®Google Scholar
• NavarraSVGuzmánRMGallacherAEEfficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trialLancet2011377976772173121296403
   PubMed Web of Science ®Google Scholar
• Lehmann-HornKSchleichEHertzenbergDAnti-CD20 B-cell depletion enhances monocyte reactivity in neuroimmunological disordersJ Neuroinflammation20118114622027448
   PubMed Web of Science ®Google Scholar
• WeberMSProd’hommeTPatarroyoJCB-cell activation influences T-cell polarization and outcome of anti-CD20 B-cell depletion in central nervous system autoimmunityAnn Neurol201068336938320641064
   PubMed Web of Science ®Google Scholar